This commentary reviews a study by Gonzalez-Rellan et al. examining the role of GLP-1 receptors on intrahepatic sinusoidal endothelial cells as mediators of semaglutide's hepatoprotective effects in MASH, independent of weight loss.
GLP-1 receptors located on intrahepatic sinusoidal endothelial cells were identified as key drivers of semaglutide's liver-protective effects in MASH, suggesting a mechanism distinct from — and beyond — weight reduction alone.
This is an editorial/commentary on a primary study; direct clinical trial data, sample sizes, and patient-level outcomes are not reported here. Translational applicability to human MASH patients cannot be fully assessed from this summary alone.
Semaglutide's benefit in MASH may stem partly from direct hepatic vascular effects, not just weight loss — clinicians should consider GLP-1 receptor agonists in MASH even when weight reduction is modest. Await the primary Gonzalez-Rellan et al. study for mechanistic and clinical details.
Explore related topics
